Pancreatic Cancer Research

ResearcherWuhan UniversityNo recent work listed

Zhengle Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0028-5432; OpenAlex author ID A5064989082. Sources: OpenAlex.

Their work

Papers
11 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: none · 2023: 2 papers

Papers 11

  1. CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-κB signaling pathway. Co-author DOI 10.1007/s10565-022-09746-w↗
  2. Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreati… First author DOI 10.1186/s13578-023-01155-8↗
  3. TRIM47 accelerates aerobic glycolysis and tumor progression through regulating ubiquitination of FBP1 in pancreatic cancer. Co-author DOI 10.1016/j.phrs.2021.105429↗
  4. The reciprocal loop of MALAT1 and HIF-1α facilitates gemcitabine resistance in pancreatic cancer by enhancing glycolysis Co-author DOI 10.21203/rs.3.rs-135235/v2↗
  5. Hypoxia-induced lncRNA CASC9 enhances glycolysis and the epithelial-mesenchymal transition of pancreatic cancer by a positive feedback loop with AKT/HIF-1α sig… Co-author PMID 33520364↗
  6. ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. Co-author DOI 10.1016/j.omto.2019.07.005↗
  7. Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cel… First author DOI 10.1186/s13578-019-0312-0↗
  8. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling. Co-author DOI 10.1186/s13046-018-0972-3↗
  9. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1111/jcmm.13126↗
  10. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade. Co-author DOI 10.1016/j.canlet.2016.08.023↗
  11. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine. First author DOI 10.18632/oncotarget.9293↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tao Yin · 7 shared papers, 2016–2023 · strength 0.72
  2. Qingke Duan · 6 shared papers, 2016–2023 · strength 0.58
  3. Chunyou Wang · 6 shared papers, 2016–2023 · strength 0.58
  4. Hehe Li · 5 shared papers, 2017–2023 · strength 0.58
  5. Heshui Wu · 5 shared papers, 2016–2023 · strength 0.56
  6. Zhi‐Gang Tang · 4 shared papers, 2018–2023 · strength 0.55
  7. Hengqiang Zhao · 5 shared papers, 2016–2021 · strength 0.44
  8. Jing Tao · 3 shared papers, 2018–2023 · strength 0.41
  9. Shihong Wu · 3 shared papers, 2019–2023 · strength 0.38
  10. Hanjun Li · 2 shared papers, 2021–2023 · strength 0.32
  11. Pei Mei · 2 shared papers, 2021 · strength 0.26
  12. Longjiang Chen · 1 shared paper, 2023 · strength 0.20
  13. Yao Guo · 1 shared paper, 2021 · strength 0.15
  14. Ming Yang · 1 shared paper, 2021 · strength 0.15
  15. Lei Li · 1 shared paper, 2021 · strength 0.15
  16. Jing Tao · 1 shared paper, 2021 · strength 0.14
  17. Kongfan Zhu · 1 shared paper, 2018 · strength 0.09
  18. Tao Liu · 1 shared paper, 2016 · strength 0.06
  19. Pengfei Shi · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.